Risk Info Should Be In Ad, Not Attached Label, FDA Says In Bystolic Ad Letter
Executive Summary
Putting product labeling at the end of a journal ad "does not mitigate the misleading omission of risk information in the body of the ad," FDA's ad division concludes in a warning letter for Forest Laboratories'Bystolic (nebivolol)
You may also be interested in...
Forest Vows To Double Pipeline Potential
Firm restates commitment to aclidinium for COPD.
Forest Hopes Efficacy In Blacks And Tolerability Will Set Bystolic Apart
With approval of Forest/Mylan's Bystolic (nebivolol) - the newest member of a crowded beta blocker class - the company is gearing up to launch with an experienced sales force, data to differentiate the drug, and a price in line with one of the most commonly used drugs in the class
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.